Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6201125 | Ophthalmology | 2014 | 7 Pages |
Abstract
Short-term, high-dose chlorambucil therapy provides sustained periods of drug-free remission. With median follow-up of more than 8 years (mean, 11.6 years; range, 4-37 years), there was a low rate of recurrence and minimal long-term serious health consequences or adverse events. Because SO may be a lifelong condition and because chlorambucil therapy may offer long-term, drug-free remission, this treatment may be worth considering early in the decision-making process for severe sight-threatening disease.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Sarju S. MD, MPH, Emilio M. MD, Laura V. MD, Cristobal A. MD, Ariel MD, Howard H. MD, Debra A. MD,